AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Incidence of Bell’s Palsy in 28 Major Markets 2019-2029: Some of these Markets are US, Canada, UK, Brazil, Japan, China, Australia & South Korea - ResearchAndMarkets.com

January 16, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 16, 2020--

The “Incidence of Bell’s Palsy in 28 Major Markets 2019-2029” report has been added to ResearchAndMarkets.com’s offering.

Bell’s palsy, also known as idiopathic facial nerve palsy, is a weakness of the muscles on one side of the face caused by the compression of the facial/cranial nerve, with no known underlying pathological cause. Such a condition typically manifests in a unilateral paralysis of the face. In rare cases, both sides of the face can be affected. Bell’s palsy is characterised by its rapid onset, reaching clinical peak within 72 hours. Most patients fully recover from Bell’s palsy.

This report provides the current incidence for Bell’s palsy across 28 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, China, Turkey, Mexico, Denmark, Egypt and South Korea, Argentina, Australia, Sweden, Denmark, Norway, Finland, The Netherlands, Poland, Russia, Switzerland, Austria ) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Bell’s palsy have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for the disease include:

This report is built using data and information sourced from our proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up-to date information from patient registries, clinical trials and epidemiology studies. All the sources used to generate the data and analysis have been identified and displayed in the report.

Reason to buy

Key Topics Covered:

For more information about this report visit https://www.researchandmarkets.com/r/nmz0w8

View source version on businesswire.com:https://www.businesswire.com/news/home/20200116005470/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/16/2020 08:40 AM/DISC: 01/16/2020 08:40 AM

http://www.businesswire.com/news/home/20200116005470/en